Deborah M. Stephens

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Bonnie K. Harrington, Susan O’Brien et al. · New England Journal of Medicine · 2015 · 891 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Bradley M. Haverkos, Diana Abbott, Mehdi Hamadani et al. · Blood · 2017 · 242 citations · Full text

Medicine, Hematology, Oncology +17

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Tanya Siddiqi, David G. Maloney, Saad S. Kenderian et al. · The Lancet · 2023 · 198 citations · Full text

Medicine, Oncology, Pharmacology +12

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

Farrukh T. Awan, Anna Schuh, Jennifer R. Brown et al. · Blood Advances · 2019 · 185 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

John C. Byrd, William G. Wierda, Anna Schuh et al. · Blood · 2019 · 178 citations · Full text

Medicine, Oncology, Pharmacology +10